PubMed Health⌕ Search

Biomedical subjects

C Huschka

Publications and source records attributed to C Huschka.

6 recordsLinked to original sources
PubMed2003

Evaluation of the anti-microbial and anti-inflammatory activities of the medicinal plants Dodonaea viscosa, Rumex nervosus and Rumex abyssinicus.

The crude extracts of the leaves of Dodonaea viscosa and Rumex nervosus as well as of the root of Rumex abyssinicus were tested for anti-microbial and anti-inflammatory activities. It was observed that the three plants possess antibacterial activity against Streptococcus pyogenes and Staphylococcus aureus and strong activity against Coxsackie virus B3 and influenza A virus. In contrast, none of them exhibited anti-fungal activity. The anti-inflammatory activity test results verified that only R. abyssinicus inhibited the synthesis of prostaglandin (PG) E(2).

Animals↗
PubMed2001

UV-induces formation of hydrogen peroxide based on the photochemistry of ketoprofen.

Ketoprofen (KP) is a potent nonsteroidal anti-inflammatory drug. However, application to the skin is problematic because the photosensitizing properties of the benzophenone moiety may cause phototoxic effects when the treated skin region is exposed to UVA light. Using capillary electrophoresis with electrochemical detection we are able to differentiate the peroxides formed during illumination of KP-containing solutions of linoleic acid. Contrary to other profens a high amount of hydrogen peroxide was found among the reaction products. For investigation of the skin damaging effect human keratinocytes were used as models. Cell viability, DNA synthesis efficiency and intracellular concentration of peroxides were determined. Viability and proliferation behavior was not altered under the influence of KP. While lower concentrations of KP (10-100 nM) led to a protection against the UVA-induced (8 J/cm2) cell proliferation damage, higher concentrations (10-100 microM) led to an amplification of the proliferation decrease. With UVB irradiation at relevant doses the effects were lower than using UVA. Furthermore, intracellular peroxide content was increased after UV irradiation and KP addition. In conclusion some efforts have to be done to avoid these side effects in the use of KP for topical or transdermal application.

Anti-Inflammatory Agents, Non-Steroidal↗
PubMed1998

Grapefruit juice increases oral nimodipine bioavailability.

The bioavailability of dihydropyridine calcium channel blockers following oral administration was shown to be increased by concomitant intake of grapefruit juice for all drugs of this class tested up to now. Here we report a randomized crossover interaction study on the effects of grapefruit juice on the pharmacokinetics of nimodipine and its metabolites. Eight healthy young men (4 smokers/4 nonsmokers) were included. Nimodipine was given as a single 30 mg tablet (Nimotop) with either 250 ml of water or 250 ml of grapefruit juice (751 mg naringin/l). Drug concentrations in plasma withdrawn up to 24 hours postdose were measured by GC-ECD, and model-independent pharmacokinetic parameters were estimated. The study was handled as an equivalence problem. Point estimators and ANOVA based 90% confidence intervals (CI) were calculated for the test (= grapefruit juice period) to reference (= water period) ratios using dose-normalized concentrations. The absence of a relevant interaction was assumed if the CIs were within the 0.67-1.50 range. Cmax for nimodipine reached 124% of the reference period (90% CI 0.76-2.01), AUC was increased to 151% (90% CI 114%-200%), respectively. The null hypothesis "relevant interaction" thus could not be rejected for the primary pharmacokinetic parameters AUC and Cmax. The ratios of metabolite AUC to parent drug AUC were slightly reduced with grapefruit juice intake. Additionally, there was evidence for a more pronounced hemodynamic response in the grapefruit juice period. To avoid the interaction, nimodipine should not be taken with grapefruit juice.

Administration, Oral↗
PubMed1981

BM 12.434, a novel compound with vasodilating and beta-adrenoceptor-blocking activities.

1. BM 12.434 was compared with a known beta-adrenoceptor-blocking agent, metipranolol, and a combination of metipranolol and isosorbide-5-mononitrate in healthy volunteers. BM 12.434 and metipranolol were given in equi-effective beta-adrenoceptor-blocking doses (reduction of exercise-increased pulse--pressure product). 2. Responses of the cardiovascular system were determined by non-invasive methods. 3. BM 12.434 increased the peripheral resistance less than metipranolol. 4. After BM 12.434, in contrast to metipranolol, both arterial flow and the venous capacity showed significant increase. 5. The combination of isosorbide-5-mononitrate and metipranolol differed from metipranolol alone mainly by the effect on venous capacity, which showed a slight increase. 6. BM 12.434 is a beta-adrenoceptor-blocking agent whose additional actions on the veins and arteries are potentially useful for the treatment of both coronary heart disease and of arterial hypertension.

Adrenergic beta-Antagonists↗